CRISPR Therapeutics (NASDAQ:CRSP) President Rodger Novak sold 75,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Thursday, May 17th. The stock was sold at an average price of $60.00, for a total value of $4,500,000.00. Following the completion of the transaction, the president now directly owns 1,183,247 shares in the company, valued at $70,994,820. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of CRISPR Therapeutics opened at $64.60 on Tuesday, according to Marketbeat Ratings. CRISPR Therapeutics has a 52-week low of $13.50 and a 52-week high of $66.70. The company has a market capitalization of $3.05 billion, a price-to-earnings ratio of -37.78 and a beta of 3.58.
Get CRISPR Therapeutics alerts:
CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Wednesday, May 9th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.05. CRISPR Therapeutics had a negative return on equity of 35.18% and a negative net margin of 189.60%. The firm had revenue of $1.36 million for the quarter, compared to analyst estimates of $3.64 million. During the same period in the previous year, the firm earned ($0.54) earnings per share. The company’s revenue was down 49.6% compared to the same quarter last year. equities research analysts anticipate that CRISPR Therapeutics will post -2.6 EPS for the current year.
Institutional investors and hedge funds have recently modified their holdings of the business. Ladenburg Thalmann Financial Services Inc. lifted its stake in CRISPR Therapeutics by 334.0% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,054 shares of the company’s stock valued at $186,000 after buying an additional 3,120 shares during the period. M&T Bank Corp acquired a new position in CRISPR Therapeutics in the first quarter valued at approximately $202,000. Element Capital Management LLC acquired a new position in CRISPR Therapeutics in the first quarter valued at approximately $210,000. BBR Partners LLC acquired a new position in CRISPR Therapeutics in the first quarter valued at approximately $229,000. Finally, LPL Financial LLC acquired a new position in CRISPR Therapeutics in the first quarter valued at approximately $256,000. 39.27% of the stock is currently owned by hedge funds and other institutional investors.
CRSP has been the topic of a number of recent analyst reports. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $53.70 price objective (down from $67.00) on shares of CRISPR Therapeutics in a research note on Friday, March 9th. Goldman Sachs initiated coverage on CRISPR Therapeutics in a research note on Friday, April 6th. They issued a “buy” rating and a $86.00 price objective on the stock. BidaskClub raised CRISPR Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 25th. Zacks Investment Research lowered CRISPR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 25th. Finally, ValuEngine raised CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. CRISPR Therapeutics currently has an average rating of “Buy” and a consensus target price of $64.28.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.